Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results

Download as PDF

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 9, 2016 at 7:30 a.m. Eastern Time to discuss financial results as of and for the year ended December 31, 2015, as well as 2015 and recent corporate highlights.

The call can be accessed by dialing (855) 465-0180 (U.S. and Canada) or (484) 756-4313 (international), and entering passcode 63684856.

To access a live audio webcast of the call, please visit the “Investors” section at investors.trevenainc.com. Following the conclusion of the call, the call will be archived and available for replay for 30 days on both the company's website and by dialing (855) 859-2056 (U.S. and Canada) or 404-537-3406 (international), and entering passcode 63684856.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to manage moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to manage moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute migraine and other CNS disorders (preclinical).

Trevena, Inc.
Jonathan Violin, Ph.D.
Sr. Director of Investor Relations
610-354-8840 x231
jviolin@trevenainc.com

Source: Trevena, Inc.

Released March 2, 2016